The rapid growth of AI, data science, and GPU-based workloads has resulted in a "data explosion," creating a widening gap between well-resourced organizations and the majority who lack GPU expertise. This disparity is particularly pronounced in the $16.5 billion simulation software market and the $600 billion cloud computing market, where prohibitive costs and limited expertise often hinder impactful R&D.
RNA technology thus has the potential to revolutionize medicine with life-saving and even curative treatments for previously unmet clinical needs, including cancers, autoimmune disorders, and neurodegenerative diseases. The primary bottleneck in the translation of the 1300+ early-stage RNA programs in existence has been the biological delivery system, not the RNA drug payload itself, due to toxicity, immunogenicity, and the inability to target specific cells, tissues, and organs, leading to off-target effects.
Skuld was founded by 2 metallurgists who did consulting to fund R&D into the AMEC process. Skuld was mothballed 20 months during COVID. The CEO went to work at Fabrisonic, a 3D printing company, and the value of the process became clear compared to other metal additive processes. Skuld was restarted in December 2021 with the CTO joining fulltime in January 2023 when we installed a small demo plant.
In fall 2024 we installed 8000 tons of melting capacity. The first problem is the existential crisis caused by global warming.
80% of all business data is structured data in the form of tables and databases. Regulatory constraints like HIPAA, CCPA & GDPR make it difficult and costly to run AI, analytics, and software development workflows on structured data. With the synthetic data market projected to grow from $600M in 2025 to $4.9B by 2032 at a 35% CAGR, there is an urgent need for scalable, efficient, and privacy-compliant solutions.
